PT-141 (Bremelanotide) 10mg

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide and selective melanocortin receptor agonist. Structurally, it is the des-amino-hydroxyl metabolite of Melanotan II, retaining the cyclic lactam bridge (Asp–Lys) with a free C-terminal hydroxyl group rather than the amide found in the parent compound. This modification confers altered receptor selectivity and improved CNS-centric activity.

PT-141 binds selectively to MC3-R and MC4-R subtypes — melanocortin receptors densely expressed in hypothalamic nuclei involved in energy balance, autonomic tone, and reward circuitry. Unlike peripheral vasodilators or hormonal agents, PT-141’s mechanism of action is mediated centrally through dopaminergic projections in the paraventricular nucleus and medial amygdala, making it a pharmacologically distinct research tool for studying central melanocortin contributions to autonomic physiology.

Research Applications

• MC3-R and MC4-R receptor binding affinity and selectivity studies
• Central melanocortin signaling and hypothalamic circuit investigation
• Dopaminergic pathway modulation via melanocortin–opioid receptor interactions
• Autonomic arousal physiology and neuroendocrine output research
• Comparative pharmacology studies vs. Melanotan II and α-MSH analogs
• CNS-mediated pathway research independent of PDE5 or hormonal mechanisms

Published Research Context

PT-141 has been characterized through multiple clinical trial programs, including the Phase 3 RECONNECT trials for hypoactive sexual desire disorder, which demonstrated statistically significant efficacy endpoints and led to the 2019 FDA approval of the pharmaceutical formulation (Vyleesi, 1.75 mg SC). Early-phase studies also explored erectile function through central dopaminergic mechanisms rather than peripheral vasodilation — a mechanistically distinct action from PDE5 inhibitors. Key pharmacological characterization includes work by Molinoff et al. (Ann N Y Acad Sci, 2003) and Pfaus et al. (Psychopharmacology, 2010) on the neurobiological underpinnings of melanocortin-mediated arousal.

Specifications

• Molecular Weight: 1,025.2 g/mol
• Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
• Structure: Cyclic heptapeptide, lactam bridge Asp³–Lys⁷
• CAS Number: 189691-06-3
• Form: White lyophilized powder
• Storage: −20°C lyophilized; 2–8°C reconstituted; protect from light
• Peplix Lot Purity: 97.071% by HPLC (Lot 2603)
• Minimum Purity: ≥97% by HPLC
• Half-life: ~2.7 hours (subcutaneous, clinical data)
• Solubility: Soluble in bacteriostatic water or sterile saline (~1 mg/mL)
• Testing Laboratory: Freedom Diagnostics

⚠ For in-vitro research use only. Not for human consumption. Not FDA approved. Certificate of Analysis included with every order.

📄 Documentation: Certificate of Analysis (Lot 2603)  |  PT-141 Compound Reference & Research Data  |  Reconstitution Calculator